These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 30808100

  • 1. Diabetic ketoacidosis following immunotherapy for lung cancer.
    Skorpen PK, Margull J.
    Tidsskr Nor Laegeforen; 2019 Feb 26; 139(4):. PubMed ID: 30808100
    [No Abstract] [Full Text] [Related]

  • 2. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 3. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
    Maamari J, Yeung SJ, Chaftari PS.
    Am J Emerg Med; 2019 Feb 01; 37(2):376.e1-376.e2. PubMed ID: 30361152
    [Abstract] [Full Text] [Related]

  • 4. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
    Mizab Mellah C, Sánchez Pérez M, Santos Rey MD, Hernández García M.
    Endocrinol Diabetes Nutr; 2017 May 01; 64(5):272-273. PubMed ID: 29056250
    [No Abstract] [Full Text] [Related]

  • 5. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
    Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM.
    J Immunother; 2017 May 01; 40(6):249-251. PubMed ID: 28557813
    [Abstract] [Full Text] [Related]

  • 6. Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy.
    Luong B, Koch G, Trivedi K, Ramachandran K.
    Am J Ther; 2017 May 01; 31(4):e474-e475. PubMed ID: 38976534
    [No Abstract] [Full Text] [Related]

  • 7. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
    Mishra T, He G, Sreeram K, Rauf M, Subahi A, Hazem M.
    Am J Ther; 2019 May 01; 26(5):e626-e627. PubMed ID: 30277909
    [No Abstract] [Full Text] [Related]

  • 8. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.
    Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, Hirsch IB.
    Diabetes Care; 2015 Sep 01; 38(9):e137-8. PubMed ID: 26116720
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 01; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 11. An unknown reaction to pembrolizumab: giant cell arteritis.
    Micaily I, Chernoff M.
    Ann Oncol; 2017 Oct 01; 28(10):2621-2622. PubMed ID: 28633343
    [No Abstract] [Full Text] [Related]

  • 12. Checkpoint inhibitors in the emergency department.
    Bachmeier CA, Morton A.
    Emerg Med Australas; 2019 Apr 01; 31(2):288-289. PubMed ID: 30690867
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW, Chaft J, Hellmann M.
    J Thorac Cardiovasc Surg; 2018 Apr 01; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract] [Full Text] [Related]

  • 15. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
    Umeguchi H, Takenoshita H, Inoue H, Kurihara Y, Sakaguchi C, Yano S, Hasuzawa N, Sakamoto S, Sakamoto R, Ashida K.
    J Oncol Pract; 2018 Jul 01; 14(7):449-451. PubMed ID: 29906213
    [No Abstract] [Full Text] [Related]

  • 16. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Jul 01; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 17. There and back again: An immunotherapy tale.
    Guo Y, Krupnick AS.
    J Thorac Cardiovasc Surg; 2018 Apr 01; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract] [Full Text] [Related]

  • 18. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.
    Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW.
    Clin Lung Cancer; 2019 Jul 01; 20(4):e489-e491. PubMed ID: 31085042
    [No Abstract] [Full Text] [Related]

  • 19. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 01; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 20. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.
    Peyrony O, Ellouze S, Fontaine JP, Mohamadou I, Zafrani L.
    Am J Emerg Med; 2020 Feb 01; 38(2):408.e3-408.e4. PubMed ID: 31759780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.